Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

27.32USD
26 May 2017
Change (% chg)

$0.06 (+0.22%)
Prev Close
$27.26
Open
$27.26
Day's High
$27.52
Day's Low
$27.19
Volume
4,828,013
Avg. Vol
7,560,331
52-wk High
$27.52
52-wk Low
$19.67

BSX

Chart for BSX

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $37,412.05
Shares Outstanding(Mil.): 1,369.40
Dividend: --
Yield (%): --

Financials

  BSX Industry Sector
P/E (TTM): 87.21 44.95 17.41
EPS (TTM): 0.31 -- --
ROI: 2.94 8.89 -5.42
ROE: 6.44 13.82 -4.68

BRIEF-Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty

* Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty

May 24 2017

BRIEF-Boston Scientific announces positive results from the Reprise III clinical trial

* The Boston Scientific LOTUS™ valve system demonstrated superior efficacy to Corevalve® in global reprise III trial at one year

May 16 2017

BRIEF-Boston Scientific closes Symetis acquisition

* To immediately begin selling Acurate TA and Acurate Neo/TF valve systems in Europe and other geographies outside of U.S. Source text for Eikon: Further company coverage:

May 16 2017

BRIEF-Boston Scientific says positive European registry results for WATCHMAN left atrial appendage closure device

* Boston scientific announces positive european registry results for watchman™ left atrial appendage closure device

May 12 2017

BRIEF-Boston Scientific announces results of study evaluating patients implanted with S-ICD System

* Announced results from U.S. post-market approval study evaluating 'real-world' patients implanted with S-ICD System

May 11 2017

India government panel rejects Boston Scientific plea on stent price caps

NEW DELHI Boston Scientific Corp stands to lose millions of dollars on its high-end heart stent in India after a government panel rejected its request to increase a cap on the price that it can charge for the device.

May 09 2017

BRIEF-Boston Scientific receives FDA approval for resonate family of high-voltage devices

* Boston Scientific receives U.S. FDA approval for resonate™ family of high-voltage devices

May 09 2017

BRIEF-Boston Scientific reports Q1 GAAP EPS $0.21

* Q1 interventional cardiology worldwide sales $605 million versus $560 million

Apr 27 2017

BRIEF-Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy

* Boston Scientific initiates global study to assess sudden cardiac arrest prevention therapy in patients with diabetes who have previously experienced a heart attack

Apr 18 2017

Boston Scientific to expand in Europe with Symetis buy

Boston Scientific Corp on Thursday agreed to buy Swiss medical device maker Symetis SA for $435 million, looking to bolster its presence in Europe after recalling a range of heart valves in the region.

Mar 30 2017

More From Around the Web

Competitors

Earnings vs. Estimates